The SARS-CoV-2 pandemic has seen a notable global reduction in influenza cases of both
influenza A and B viruses. In particular, the B/Yamagata lineage has not been isolated from …

Seasonal influenza viruses cause recurring global epidemics by continually evolving to
escape host immunity. The viral constraints and host immune responses that limit and drive …

The rapid emergence of coronavirus disease 2019 (COVID-19) as a global pandemic
affecting millions of individuals globally has necessitated sensitive and high-throughput …

The global outbreak of a novel severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) highlighted a requirement for two pronged clinical interventions such as …

Abstract Design of nucleic acid-based viral diagnostics typically follows heuristic rules and,
to contend with viral variation, focuses on a genome's conserved regions. A design process …

The global dynamics of seasonal influenza viruses inform the design of surveillance,
intervention, and vaccination strategies. The COVID-19 pandemic provided a singular …

Influenza is a leading cause of death in the elderly, and the vaccine protects only a fraction
of this population. A key aspect of antibody-mediated anti-influenza virus immunity is …

Influenza B virus primarily infects humans, causing seasonal epidemics globally. Two
antigenic variants—Victoria-like and Yamagata-like—were detected in the 1980s, of which …

Influenza B viruses have circulated in humans for over 80 y, causing a significant disease
burden. Two antigenically distinct lineages (“B/Victoria/2/87-like” and “B/Yamagata/16/88 …

Influenza B virus (IBV) infections can cause severe disease in children and the elderly.
Commonly used antivirals have lower clinical effectiveness against IBV compared to …